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Objectives: SAGIT is a clinician-reported outcome tool designed to help endocri-
nologists describe acromegaly patients and disease activity in their everyday prac-
tice. SAGIT records five elements of the disease: Signs and symptoms (S), Associated 
comorbidities (A), GH concentration (G - either assessed as GH nadir after oral glu-
cose tolerance test or GH random or series), IGF-1 concentration (I) and Tumor (T). 
The objectives of the present work were to assess acceptability, understanding 
and possible uses of SAGIT with endocrinologists in real conditions. MethOds: 
Endocrinologists from France (n= 2), Germany (n= 1), Italy (n= 2), Spain (n= 2) and 
United States (n= 2) completed SAGIT for patients with active acromegaly (n= 9), 
controlled/stable acromegaly (n= 10) and treatment-naïve patients (n= 7). After com-
pletion of SAGIT, endocrinologist’s reported their perception and opinion of the tool 
using the PRAgmatic Content and face validity Test. Results: Endocrinologists 
had no difficulties completing the S, A, I and T elements of SAGIT and reporting the 
respective scores based on their patients’ data. Both GH nadir after oral glucose load 
and GH random or series were informed by most endocrinologists while informa-
tion for one of the two elements only is required. The majority of endocrinologists 
deemed the information retrieved from SAGIT useful, either for research purpose 
(n= 7), decision-making (n= 6), or response therapy assessment (n= 5). They found 
it concise, easy to understand and unbiased (n= 8), and simple, quick to complete 
and informative (n= 7). Scores and decision rules and interpretation were among 
the aspects that required improvement. Scores of each elements of SAGIT vary 
according to patient’s acromegaly status. cOnclusiOns: Face and content validity 
of SAGIT are demonstrated, as is its applicability in clinical practice and research. It 
seems a promising tool for staging and classifying acromegaly patients. The planned 
validation study will allow the definition of scoring rules, interpretation and recom-
mendations for managing patients in clinical practice.
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Objectives: To synthesize the available information on the therapeutic value of 
dipeptidyl peptidase-4 inhibitors (DPP-4) for the treatment of type 2 diabetes mellitus 
(T2DM) from the point of view of the patient-reported outcomes (PROs). MethOds: 
A systematic review was performed on International (Pub Med, WOK, Scopus, 
Cochrane Library) and Spanish (IBECS, MEDES) databases. Observational studies and 
narrative or systematic reviews regarding T2DM patients and use of DPP-4 inhibitors 
until June 2013 were selected. Results: We identified 1,713 publications; 317 were 
excluded after duplicate review, 1,383 by title/abstract review and 9 after applying 
inclusion criteria (n= 9). A total of 4 studies conducted in Italy (n= 1), Germany (n= 1), 
USA (n= 1), and one international (including Spain) were selected. Three publications 
had a retrospective design and 1 was prospective. Two studies reported information 
about adherence/persistence, one about satisfaction and one about preferences. No 
information about HRQoL was identified. Patients receiving DPP-4 inhibitors were 
more likely to be adherent than those treated with Glucagon-like peptide-1 (GLP-1) 
agonists [Odds Ratio= 0.40; 95% CI= 0.37-0.42], sulfonylurea [OR= 0.49; 95% CI= 0.46-
0.52] or thiazolidinediones [OR= 0.54; 95% CI= 0.51-0.57]; moreover, DPP-4 inhibitors 
were associated with a lower risk of treatment discontinuation [Hazard Ratio= 0.74; 
95% CI= 0.71-0.76], explained by a greater tolerability and a lower risk of hypoglyce-
mia. Combination of DPP-4 inhibitors and metformin increased patient’s satisfac-
tion by a 30%, associated with higher control of glucose levels. Most of the patients 
preferred DPP-4 inhibitors to GLP-1 agonists (85% vs. 15%; p< 0.001) as first option. In 
the Spanish population, the proportion of patients preferring DPP-4 inhibitors was 
even higher (90.4% vs. 9.6%; p< 0.001). cOnclusiOns: PROs in DPP-4 inhibitors are 
poorly described in the literature. Nevertheless DPP-4 inhibitors are preferred as first 
option and are associated with higher persistence and satisfaction, mainly due to 
higher perception of glycemic control of glucose level and lower hypoglycemia risk.
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Objectives: The objective of the study is to assess the cost of continuous sub-
cutaneous insulin infusion (CSII) application for children with diabetes type 1 in 
Sofia, Bulgaria and to compare the changes in BMI and HbA (1c), of three groups of 
children- with diabetes – applying insulin pens with human insulin, with analog 
insulin and children with insulin pumps. MethOds: The study was performed from 
the point of view of the health insurance fund and patients. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Cost of CSII, blood glucose monitoring system and strips was 
calculated. The primary outcome observed was the variation in HbA (1c) and the 
secondary was the BMI change. 51 children were observed. The data collected from 
the patients’ dossier including demographics about their age, sex, weight, duration 
of disease and HbA (1c) and type of treatment (CSII or analogue insulin treatment 
with a pen device). Results: The total yearly cost weighed with the duration of 
the disease is 1850 Euro (30% reimbursed). The average improvement of HbA (1c) 
after the CSII introduction is 1.72 and the average BMI was 37.03. cOnclusiOns: 
Improvements in glycemic control associated with CSII led to reduced HbA (1c) 
reported here. Results: Overall, 1,038 respondents (T1DM= 466, T2DM= 572) com-
pleted 3,528 questionnaires. Mean insulin treatment duration was 11.7 years and 
mean HbA1c was 8.2% (66.2 mmol/mol). Mean NSHE/week was 2.4 (T1DM) and 0.8 
(T2DM); 23% (T1DM) and 26% (T2DM) occurred at night. Fatigue and reduced alert-
ness were the commonest sequelae of NSHEs (78% and 51% of respondents, respec-
tively). Effects of nocturnal NSHEs lasted significantly longer than effects of daytime 
events: T1DM= 10.6 vs. 4.9 hours (p= 0.0002); T2DM= 15.3 vs. 5.1 hours (p< 0.0001). 
In the week following a NSHE, blood glucose testing increased 12% (T1DM) and 
21% (T2DM). In employed respondents (47% of total), 20% of NSHEs caused loss of 
work-time, which was longer following nocturnal NSHEs: T1DM= 2.7 vs. 1.1 hours 
(p= 0.0184); T2DM= 2.5 vs. 1.6 hours (p= 0.1340). Over a third of employed respond-
ents experienced difficulty concentrating at work following NSHEs (T1DM= 39%; 
T2DM= 44%). Respondents contacted a health care professional (HCP) after 3% 
(T1DM) and 7% (T2DM) of NSHEs. Overall, respondents rarely or never informed 
HCPs about NSHEs (T1DM= 82%; T2DM= 69%). cOnclusiOns: NSHEs are common 
in adults with insulin-treated diabetes in the UK, and have a negative impact on 
personal well-being, work productivity, and health care resource use. As they are 
seldom reported to HCPs, the burden of hypoglycaemia may be underestimated.
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Objectives: The aim of the empirical study is to evaluate patients’ preferences for 
different characteristics of treatment in type2 diabetes mellitus (T2DM). As T2DM 
treatment asks for strict adherence, patient’s needs and preferences should be taken 
into consideration. MethOds: Based on a qualitative and quantitative analysis 
a Discrete Choice Experiment (DCE) was applied to identify patient preferences. 
Apart from six identical attributes (adjustment of glycated hemoglobin [HbA1c], 
prevention of hypoglycemia, risk of genital infection, risk of gastrointestinal prob-
lems, risk of urinary tract infection and weight change) one continuous variable of 
either healthy life years equivalents (HYE) or money equivalents (ME) was included. 
The DCE was conducted using a fractional factorial design and the statistical data 
analysis used random effect logit models. Results: In total N= 626 (N= 318 HYE + 
N= 308 ME) T2DM patients participated in the survey. The estimation revealed a clear 
dominance for prevention of hypoglycemia (coefficient: 0,937) and adjustment of 
HbA1c (coefficient: 0,541). The attributes, additional healthy life years (coefficient: 
0,458) or additional cost (coefficient: 0,420) were in the middle rank and both of 
significant impact. The side effects, risk of genital infection (coefficient: 0,301), risk 
of gastrointestinal problems (coefficient: 0,296) and risk of urinary tract infection 
(coefficient: 0,241) followed in this order. Possible weight change (coefficient: 0,047) 
was of less importance (last rank) to the patients in this evaluation. cOnclusiOns: 
These survey results demonstrate how much a treatment characteristic of a (hypo-
thetical) oral diabetes treatment affects the treatment decision Understanding how 
patients perceive and value different aspects of oral T2DM treatment is vital to the 
optimal design and evaluation of treatment options. (IB 209403011/14).
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Objectives: Only a few studies have explored deriving clinically relevant time-
equivalents in comparison to money-equivalents from Discrete-Choice Experiment 
(DCE) data. By separating the decision model and including a) healthy life-years 
equivalents (HYEsurvey) or b) money equivalents (MEsurvey) it could be derived 
if both lead to similar preference patterns and allow answering the question: Can 
HYE or ME serve as identical “currency” for patients with type2 diabetes mellitus 
(T2DM) patients? MethOds: A DCE, separated into two versions, was applied to 
identify patient preferences in oral diabetes treatment. Six identical attributes and 
one continuous variable of either HYE or ME were included. To be able to test the 
rescaling effect a scope test has been included, by using different level ranges of 
the time/money attribute. DCE used a fractional factorial design and random effect-
logit-models (Stata, xtlogit and gllamm). Results: The estimation of the N= 626 
(N= 318HYE+N= 308ME) datasets of T2DM patients revealed similar preference pat-
terns for both survey version were prevention of hypoglycemia (coefficient. HYE: 
0,937; coefficient. ME: 0,847) and adjustment of hemoglobin A1c (HbA1c) (coefficient. 
HYE: 0,541; coefficient. ME: 0,649) occurred on first rank. Additional healthy life years 
(coefficient. HYE: 0,458) or additional cost (coefficient. ME: 0,420) ranked in middle 
positions. Side effects of risk of genital infection (coefficient. HYE: 0,301; coefficient. 
ME: 0,416), risk of gastrointestinal problems (coefficient. HYE: 0,296; coefficient. ME: 
0,408) and risk of urinary tract infection (coefficient. HYE: 0,241; coefficient. ME: 
0,355) followed accordingly. Possible weight change (coefficient. HYE: 0,047; coef-
ficient. ME: 0,067) showed no significant effect in this evaluation. cOnclusiOns: 
For the first time the methods of HYE and ME were used in one study to be able to 
compare patients’ preferences regarding those two continuous currencies (HYE/
ME) of treatment in T2DM, as well as the influence of those criteria on the patient 
decision patterns and patient benefit. Therefore, as HYE and ME led to comparable 
preference patterns, both can be discussed as summary measures of health out-
come, in interchangeable ways, but further research is needed. (IB 209203011/14)
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questionnaire. Diabetes control was defined as Hb1Ac ≤ 7%. Results: The major-
ity of the sample were male (55%) and overweight (59% had BMI 25-29.9). 20.4% of 
T2DM patients had a history of laboratory-confirmed hypoglycemia. In total, 59% 
had HbA1c > 7%. The mean age was 60 and the mean T2D duration was 10 years. The 
mean QoL score of the total sample was -3.1± 1.9, the mean score of non-hypogly-
cemic patients was -3.05 ± 2.0 while the respective score of hypoglycemic patients 
was -3.26 ±1.8, (p≤ 0.005). Similar results were observed in the group of controlled 
patients and uncontrolled patients, who scored -2.73±1.7 and -3.33±1.9, respectively 
(p≤ 0.005). Comparable results were identified in the majority of the ADDQoL-19 
instruments’ dimensions. According to the logistic regression analysis the majority 
of the ADDQoL-19 dimensions were significantly affected by hypoglycemia, as well 
as by high levels of HbA1c. cOnclusiOns: The study confirmed that the QoL of 
Greek T2D patients is negatively affected by hypoglycemic events and the level of 
the disease control. In T2D, treatment should attain good glycemic control without 
debilitating hypoglycemic episodes, which compromise patients’ QoL.
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Objectives: Two surveys were conducted to assess the impact of nocturnal and 
daytime hypoglycaemia on the individual and on the Turkish economy. MethOds: 
People with diabetes who had experienced a non-severe hypoglycaemic event in 
the 4 weeks prior to the survey were eligible for inclusion. The surveys were con-
ducted face to face; all information, including hypoglycaemic events, was self-
reported. Results: In the Turkish cohort, 95 people responded (50 for the nocturnal 
survey [N]; 55 for the daytime survey [D]). Mean age was 49 years/48 years (N/D), 
mean weight was 76.9 kg/75.2 kg (N/D), 40%/31% (N/D) of respondents were male, 
and 64%/80% (N/D) had type 2 diabetes. Among respondents with type 2 diabetes, 
63%/48% (N/D) received insulin ± OADs and 63%/66% (N/D) received OADs ± insu-
lin. Non-severe hypoglycaemic episodes were experienced at least once/week by 
20%/35% (N/D) and at least once/month by 58%/73% (N/D) of respondents. After the 
non-severe nocturnal (N) /daytime (D) hypoglycaemic event, 16% and 9% (N/D) of 
respondents decreased their insulin dose and 16% and 20%, respectively, contacted 
a health care professional. On average, respondents used 1.5 or 1.6 (N/D) extra blood 
glucose tests the following week, and 34%/26% (N/D) of those surveyed reported a 
high level of fear of a hypoglycaemic event. Of respondents who worked for pay 
(n= 22/17), 59%/77% (N/D) reported a high/medium impact on work productivity fol-
lowing a hypoglycaemic event. Mean time to return to sleep following a nocturnal 
event was 60 minutes; 28% reported that the event had a high impact on sleep, and 
54% had difficulty focusing at work the next day. cOnclusiOns: In Turkey, noctur-
nal and daytime non-severe hypoglycaemic events impact quality of life, utilisation 
of health care resources and productivity in people with diabetes.
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Objectives: Weight control is a cornerstone of type 2 diabetes (T2DM) management, 
but the impact of losing small to moderate amounts of weight relative to gaining 
weight on patient-reported outcomes and resource use among T2DM patients is 
not widely reported. This study was conducted to describe the association of weight 
change in T2DM patients taking steps to lose weight (TSLW) with HRQoL, work pro-
ductivity and resource use in European T2DM patients. MethOds: Data came from 
the 2013 5EU National Health and Wellness Survey, representative of adults in France, 
Germany, Italy, Spain and the United Kingdom. Respondents TSLW who lost ≤ 5kg were 
compared to respondents who gained weight. Outcome measures included SF-36v2, 
Work Productivity & Activity Impairment Questionnaire, and 6-month self-reported 
health care use. Comparisons used pairwise t-tests and chi-square tests for continu-
ous and categorical variables, respectively. Results: Of 1,985 respondents taking 
steps to lose weight, 61% were male, 37% were employed with mean BMI 32.3 kg/
m2. Relative to respondents who gained weight (n= 354), respondents who lost ≤ 5kg 
(n= 560) had higher scores on mental component summary by 3.9 points (p< 0.05), 
higher physical component summary by 2.3 points (p< 0.05), and SF-6D health utility 
by 0.05 points (p< 0.05). This group reported lower work and activity impairment as 
well as lower health care resource utilisation relative to those who gained weight, with 
lower mean presenteeism (22% vs. 28%, p< 0.05), activity impairment (34% vs. 44%, 
p< 0.05), health care provider visits (7.8 vs. 10.2 p< 0.05), emergency room visits (0.2 
vs. 0.6; p< 0.05) and hospitalizations (0.2 vs. 0.4; p< 0.05). cOnclusiOns: Treatments 
which facilitate small to moderate weight loss may offer T2DM patients better HRQoL 
and potentially offer savings to the health care system when compared to treatments 
which promote weight gain. Further research is required to explain this observation.
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Objectives: Adults with developmental disabilities have higher prevalence of chronic 
disease conditions such as diabetes, obesity, high blood pressure, arthritis, CVD and 
chronic pain. They also have poor health care utilization and screened less for chronic 
disease conditions. The objective of this study was to examine the association of race, 
and medication adherence, and their interaction with health care utilization and 
health care costs in Medicaid enrollees with developmental disabilities (DD) and type 
that can guarantee good diabetes management, but its control over BMI in growing 
children is still unclear. The insulin pumps have too many advantages: reduction 
in insulin requirements, reduced variability of insulin absorption, decreased hypo-
glycemia incidents, avoided pain, improved quality of life.
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Objectives: Diabetes Mellitus is one of the most expensive common diseases. 
Because of the great socio-economic importance of this indication, it seems neces-
sary to consider the expectations and needs of all patients with regard to treat-
ment characteristics. To evaluate patient preferences stated-preference methods 
are increasingly used. The aim was to analyze and compare the available evidence 
from patient preference studies regarding the treatment characteristics and to dis-
play which target criteria are most important from the patients view. MethOds: A 
literature review in PubMed was conducted to identify stated preference studies in 
the indication of diabetes and show which properties of a treatment are relevant 
to the patient’s benefit. By means of level difference calculation and a subsequent 
normalization uniform weights for the attributes of the studies were determined. 
Based on a final ranking the key criteria according to their value proposition from 
the perspective of affected populations are demonstrated. Results: N= 13 studies 
could be included in the analysis. By calculating the level difference and performing 
a normalization it was possible to obtain a uniform representation of all attributes 
of each study. The analysis includes the presentation and analysis of DCE-studies 
which have illustrated the determined coefficients. The studies show that blood 
sugar control, side effects (such as hypoglycemia, nausea/stomach discomfort, 
weight changes), long-term complications (especially cardiovascular disease) and 
mode of administration represent the most patient-relevant outcomes in diabetes 
therapy. Blood glucose control achieved the highest ranking within the relative 
importance score. cOnclusiOns: Based on the findings of this systematic review 
the evidence of patient preferences in diabetes treatment is synthesized. The results 
show the relative importance based on a derived ranking score of the used patient-
relevant endpoints. The determined ranking allows the comparison of the results of 
the identified preference studies and might solve the problem of scale heterogeneity.
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Objectives: The Hypoglycaemia Perspectives Questionnaire (HPQ) is a patient-
reported outcomes (PRO) instrument assessing diabetic patients’ experience 
and perceptions of hypoglycaemia. The aim of this study is to evaluate the factor 
structure and psychometric characteristics of the HPQ in type 2 diabetic patients 
(T2DM). MethOds: HPQ was administered to adults with T2DM in a clinical sample 
from Cyprus and a community sample in the US from 2011 US National Health and 
Wellness Survey. Demographic and clinical data were collected. Participants com-
pleted the Audit of Diabetes Dependent Quality of Life (ADDQoL-19), treatment sat-
isfaction items, and EuroQol-5 Dimensions (EQ-5D) (Cyprus only). HPQ items assess 
hypoglycaemia attitudes and behaviours on an 11-point numeric rating scale (NRS). 
Item performance and factor structure were examined and measurement properties 
(reliability, construct validity, known-groups validity) evaluated. Results: Cyprus 
(n= 500) and US (n= 1,257) T2DM samples were of similar age (Cyprus 61.0±10 years, 
US 59.9±11 years). Cyprus had more males (67.4% vs. 54.2%) and fewer obese sub-
jects (BMI ≥ 30) 45.6% vs. 67.8%) than the US. More US subjects reported hypoglycae-
mia events in the past seven days (27.7% vs. 16.6% with ≥ 1 event). Prescription oral 
diabetes medications were used by 90.3% of Cyprus participants and 83.6% of US 
participants, and insulin by 32.9% and 25.3%, respectively. Analyses supported three 
HPQ domains: Symptom Concern (six items), Compensatory Behavior (five items), 
and Worry (five items). Internal consistency was high for all three domains (all ≥ 0.75), 
supporting reliability. Convergent validity was supported by moderate correlations 
between HPQ domain scores and ADDQoL-19 total score. Patients with recent hypo-
glycaemia events had significantly higher HPQ scores supporting known-group valid-
ity. cOnclusiOns: HPQ is a valid and reliable measure capturing the experience and 
impact of hypoglycaemia and can be useful in clinical trial and community-based 
settings.
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Hypoglycemia (Hypo) is a common adverse effect of type 2 diabetes (T2D) therapy. 
Hypo has a negative impact on health care resources and quality of life (QoL) and 
can affect compliance and T2D control. Objectives: To estimate the impact of 
Hypo on the QoL as well as its prevalence on T2D patients in Greece. MethOds: A 
cross-sectional epidemiological study was conducted in 6631 patients with T2DM. 
Hypo events with different treatment regimens, T2D control rates and QoL were 
assessed. Hypo episodes were defined as laboratory-confirmed (< 70 mg/dl) symp-
tomatic events. QoL was measured using the patient-administered ADDQoL-19 
